Table 6.
Event-free survival
| Event Free Survival (median number of days; interquartile range)a | Tosedostat 120 mg N=38 |
Tosedostat 240 mg→120 mg N=35 |
Overall N=73 |
|---|---|---|---|
|
| |||
| All patients | 56 (28, 85) | 41 (26, 90) | 54 (28, 85) |
|
|
|||
| PR or Better | 125.5 (84.5, 168.5) n=8 | 142.5 (104, 170) n=8 |
142.5 (84.5,169.5) n=16 |
| CR/CRp/MLFS | 167 (125.5, 173) n=4 |
170 (143, 170) n=5 |
168 (143, 170) n=9 |
| PR | 84.5 (70, 127) n=4 |
67 (30, 142) n=3 |
84 (56, 142) n=7 |
| SD | 63 (56, 86) n=14 |
58 (56, 109) n=7 |
58 (56, 86) n=21 |
| PD/Non-evaluable |
26.5 (9, 28) n=16 |
28·5 (18, 37.5) n=20 |
27.5 (12.5, 31) n=36 |
a
Event Free Survival is defined as the time (in days) from the date of first dose to the occurrence of an event. An event is defined as the earliest of the following: death (from any cause); disease progression; change and/or discontinuation of therapy for any reason at any time during the study. Subjects who do not have an event are censored at the end of study.
CR=complete remission; CRp=complete remission with incomplete platelet recovery; MLFS=morphological leukaemia-free state; PR=partial remission; SD=stable disease; PD=progressive disease;